切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2016, Vol. 05 ›› Issue (01) : 11 -15. doi: 10.3877/cma.j.issn.2095-3224.2016.01.03

所属专题: 文献

专家论坛

胃癌放射治疗进展
朱远1,()   
  1. 1. 310022 杭州,浙江省肿瘤医院放疗科,浙江省放射治疗学重点实验室
  • 收稿日期:2016-02-14 出版日期:2016-02-25
  • 通信作者: 朱远
  • 基金资助:
    浙江省自然科学基金(LY14H60009)

Advances of radiotherapy for gastric cancer

Yuan Zhu1,()   

  1. 1. Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Radiation Oncology, Hangzhou 310022, China
  • Received:2016-02-14 Published:2016-02-25
  • Corresponding author: Yuan Zhu
  • About author:
    Corresponding author: Zhu Yuan, Email:
引用本文:

朱远. 胃癌放射治疗进展[J]. 中华结直肠疾病电子杂志, 2016, 05(01): 11-15.

Yuan Zhu. Advances of radiotherapy for gastric cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 05(01): 11-15.

胃癌是国内外常见的恶性肿瘤之一,手术是胃癌的主要治疗手段,但局部晚期胃癌单纯手术很难达到根治。化疗在局部晚期胃癌新辅助及辅助治疗中的地位已比较肯定,但放疗或放化疗的地位仍有争议。

Gastric cancer is one of the most common malignancy in the world, surgery is the main treatment management of gastric cancer, but surgery alone is difficult for the radical treatment in locally advanced gastric cancer. The role of neoadjuvante and adjuvante chemotherapy in advanced gastric cancer is sure, but the role of radiotherapy or chemoradiocherapy is yet controversial.

[1]
陈万青,张思维,曾红梅,等.中国肿瘤登记地区2010年恶性肿瘤发病和死亡分析.中国肿瘤,2014,23(1): 1-10.
[2]
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2015. CA Cancer J Clin, 2015, 65(1): 5-29.
[3]
Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA, 2010, 303(17): 1729-1737.
[4]
Zhang ZX, Gu XZ, Yin WB, et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)-report on 370 patients. Int J Radiat Oncol Biol Phys, 1998, 42(5): 929-934.
[5]
Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol, 2004, 22(14): 2774-2780.
[6]
Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol, 2005, 23(6): 1237-1244.
[7]
Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol, 2006, 24(24): 3953-3958.
[8]
Trip AK, Poppema BJ, van Berge Henegouwen MI, et al. Preoperative chemoradiotherapy in locally advanced gastric cancer, a phase I/II feasibility and efficacy study. Radiother Oncol, 2014, 112(2): 284-288.
[9]
Fields RC, Strong VE, Gonen M, et al. Recurrence and survival after pathologiccomplete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. Br J Cancer, 2011, 104(12): 1840-1847.
[10]
Diaz-Gonzalez JA, Rodriguez J, Hernandez-Lizoain JL, et al. Patterns of response after preoperative treatment in gastric cancer. Int J Radiat Oncol Biol Phys, 2011, 80(3): 698-704.
[11]
Pepek JM, Chino JP, Willett CG, et al. Preoperative chemoradiotherapy for locally advanced gastric cancer. Radiation Oncology, 2013, 8(1): 6-13.
[12]
Kumagai K, Rouvelas I, Tsai JA, et al. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: A direct and adjusted indirect comparison meta-analysis. Eur J Surg Oncol, 2015, 41(3): 282-294.
[13]
Leong T, Smithers M, Michael M, et al. TOPGEAR: An international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG). J Clin Oncol, 2012, 30 (15 Suppl): TPS4141.
[14]
Martinez-Monge R, Calvo A F, Azinovic I. Patterns of Failure and Long-Term Results in High-Risk Resected Gastric Cancer Treated With Postoperative Radiotherapy With or Without Intraoperative Electron Boost. J Surg Oncol, 1997, 66(1): 24-29.
[15]
Glehen O, Peyrat P, Beaujard AC, et al. Pattern of failures in gastric cancer patients with lymph node involvement treated by surgery, intraoperative and external beam radiotherapy. Radiother Oncol, 2003, 67(2): 171-175.
[16]
Calvo F, Sole C, Obregon R, et al. Intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma: topography of locoregional recurrences and long-term outcomes. Clin Transl Oncol, 2013, 15(6): 443-449.
[17]
Fu S, Lu JJ, Zhang Q, et al. Intraoperative radiotherapy combined with adjuvant chemoradiotherapy for locally advanced gastric adenocarcinoma. Int J Radiat Oncol Biol Phys, 2008, 72(5): 1488-1494.
[18]
Debenham B, Hu K, Harrison L. Present status and future directions of intraoperative radiotherapy. Lancet Oncol, 2013, 14(11): e457-464.
[19]
Zhang Q, Tey J, Peng L, et al. Adjuvant chemoradiotherapy with or without intraoperative radiotherapy for the treatment of resectable locallyadvanced gastric adenocarcinoma. Radiother Oncol, 2012, 102(1): 51-55.
[20]
Drognitz O, Henne K, Weissenberger C, et al. Long-term results after intraoperative radiation therapy for gastric cancer. Int J Radiat Oncol Biol Phys, 2008, 70(3): 715-721.
[21]
D′Angelica M, Gonen M, Brennan MF, et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg, 2004, 240(5): 808-816.
[22]
Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol, 2012, 30(19): 2327-2333.
[23]
Fuchs CS, Tepper JE, Niedzwiecki D, et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol, 2011, 29(15_suppl; abstr 4003): 256s.
[24]
Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: The ARTIST trial. J Clin Oncol, 2012, 30(3): 268-273.
[25]
Park SH, Sohn TS, Lee J, et al. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. J Clin Oncol, 2015, 33(28): 3130-3136.
[26]
Zhu WG, Xua DF, Pu J, et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol, 2012, 104(3): 361-366.
[27]
Dikken JL, van Sandick JW, Maurits Swellengrebel HA, et al. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS) . BMC Cancer, 2011, 11: 329.
[28]
Qin H L, Lin CH, Zhang XL. Evaluation of intraoperative radiotherapy for gastric carcinoma with D2 and D3 surgical resection. World J Gastroenterol, 2006, 12(43): 7033-7037.
[1] 衣晓丽, 胡沙沙, 张彦. HER-2低表达对乳腺癌新辅助治疗疗效及预后的影响[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 340-346.
[2] 谭巧, 苏小涵, 侯令密, 黎君彦, 邓世山. 乳腺髓样癌的诊治进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 366-368.
[3] 杨小菁, 姜瑞瑞, 石玉香, 王静静, 李长天. 乳腺孤立性纤维性肿瘤一例[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 375-377.
[4] 彭旭, 邵永孚, 李铎, 邹瑞, 邢贞明. 结肠肝曲癌的诊断和外科治疗[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 108-110.
[5] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[6] 陈垚, 徐伯群, 高志慧. 改良式中间上入路根治术治疗甲状腺癌的有效性安全性研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 619-622.
[7] 孔博, 张璟, 吕珂. 超声技术在复杂腹壁疝诊治中的作用[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 670-673.
[8] 姜明, 罗锐, 龙成超. 闭孔疝的诊断与治疗:10年73例患者诊疗经验总结[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 706-710.
[9] 杨瑞洲, 李国栋, 吴向阳. 腹股沟疝术后感染的治疗方法探讨[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 715-719.
[10] 陆志峰, 周佳佳, 梁舒. 虚拟现实技术在治疗弱视中的临床应用研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 891-895.
[11] 李田, 徐洪, 刘和亮. 尘肺病的相关研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 900-905.
[12] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
[13] 李变, 王莉娜, 桑田, 李珊, 杜雪燕, 李春华, 张兴云, 管巧, 王颖, 冯琪, 蒙景雯. 亚低温技术治疗缺氧缺血性脑病新生儿的临床分析[J]. 中华临床医师杂志(电子版), 2023, 17(06): 639-643.
[14] 戴俊, 李硕, 曹影, 汪守峰, 宋红毛, 蔡菁菁, 邵敏, 陈莉, 程雷, 怀德. 鼻内镜下改良高选择性翼管神经低温等离子消融术对中重度变应性鼻炎的效果研究[J]. 中华临床医师杂志(电子版), 2023, 17(06): 689-693.
[15] 符梅沙, 周玉华, 李慧, 薛春颜. 淋巴细胞免疫治疗对复发性流产患者外周血T淋巴细胞亚群分布与PD1/PD-L1表达的影响及意义[J]. 中华临床医师杂志(电子版), 2023, 17(06): 726-730.
阅读次数
全文


摘要